MannKind Corp (NASDAQ:MNKD)

CAPS Rating: 3 out of 5

A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer.


Player Avatar CromulentBrad (52.71) Submitted: 4/8/2013 11:25:44 AM : Outperform Start Price: $2.37 MNKD Score: +74.46

all comparisons to pfizer's failed product are silly & not based on facts. simply having knowledge of pfizer's product is hardly enough to make a proper comparison.

afrezza will get fda approval. it will have a profound impact on the lives of millions of diabetics. this is product people want and need. this is not some pie-in-the-sky notion from a science fiction novel. mannkind is on the verge of a monumental medical breakthrough.

Member Avatar Kimamarie (< 20) Submitted: 8/17/2013 6:31:59 PM
Recs: 0

I agree I 'm a hospital pharmacist and feel eliminating any medication injection is big advantage .However none of the articles I've read mention its biggest advantage. Insulin is one off the most dangerous medications on the market. Every year thousands of dosing errors causing injury and death. A measured metered dose inhaler will help eliminate these errors.

Featured Broker Partners